Aethlon Medical IncNASDAQ:AEMD
- LAST PRICE1.5300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6080/ 2
- Ask / Lots1.7000/ 1
- Open / Previous Close0.0000 / 1.5300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AEMD |
|---|---|---|
| 09:54 ET | 100 | 1.51 |
| 02:33 ET | 150 | 1.53 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aethlon Medical Inc | 4.0M | -0.3x | --- |
Helius Medical Technologies Inc | 4.3M | 0.0x | --- |
Catheter Precision Inc | 4.4M | 0.0x | --- |
Alseres Pharmaceuticals Inc | 153.2K | 0.0x | --- |
Guided Therapeutics Inc | 5.6M | -1.4x | --- |
Kelyniam Global Inc | 1.5M | -2.0x | --- |
Company Information
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
Contact Information
- Headquarters
- 11555 Sorrento Valley Road, Suite 203SAN DIEGO, CA, United States 92121
- Phone
- 858-459-7800
- Fax
- ---
Executives
- Independent Chairman of the Board
- Edward Broenniman
- Interim Chief Executive Officer, Chief Financial Officer, Senior Vice President - Finance, Company Secretary, Director
- James Frakes
- Chief Operating Officer, Senior Vice President
- Guy Cipriani
- Chief Scientific Officer
- Lee Arnold
- Chief Medical Officer
- Steven Larosa
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.0M |
|---|---|
Revenue (TTM) | $574.3K |
Shares Outstanding | 2.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.94 |
EPS | $-5.03 |
Book Value | $6.55 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 7.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,199.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
